Medication info
Sitapluse Sustained Release Tablet 50/1000 mg (Sitagliptin, Metformin)

Sitapluse Sustained Release Tablet 50/1000 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Bright green oval sustained-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202301869 · Approved 2023.06.20 · Insurance code 648604590

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine as a 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes through the combined action of sitagliptin and metformin. It is an adjunct to diet and exercise for effective blood sugar management, improving symptoms of diabetes and supporting the maintenance of healthy blood sugar levels.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine as a 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication is a diabetes treatment that contains sitagliptin and metformin, aiding in blood sugar control. Caution should be exercised for allergic reactions while taking this medication. Rarely, anaphylaxis, angioedema, and serious skin conditions may occur, so if symptoms such as skin rash or difficulty breathing arise, stop taking the medication immediately and consult a physician. Also, this medication may potentially cause pancreatitis, so if symptoms of pancreatitis such as abdominal pain, vomiting, or loss of appetite occur after taking, inform your healthcare provider immediately. The metformin component can lead to a dangerous condition known as lactic acidosis in severe cases; hence, patients with renal dysfunction or certain diseases such as dehydration, severe infection, or heart failure should not take it. Particularly, patients with moderate to severe renal impairment, those with acute heart failure, and those undergoing tests with iodinated contrast media should avoid using this medication, as should pregnant or breastfeeding women. Attention is required as irregular meal patterns, excessive exercise, or taking certain medications may increase the risk of lactic acidosis or hypoglycemia. This medication contains tartrazine (Yellow No. 4) dye, so it should be taken cautiously by those who are allergic to this component. During treatment, gastrointestinal disturbances such as nausea, diarrhea, or abdominal pain may occur, and in rare cases, hypoglycemia or skin rashes may arise. Before taking the medication, it is essential to consult with a doctor or pharmacist to ensure it is appropriate for your health condition, and any unusual symptoms should be discussed with a specialist immediately.

Side effects

  • severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. Proper storage can help preserve the efficacy and safety of the medication for an extended period.

Appearance and packaging

Appearance

Bright green oval sustained-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.